Molecular hydrogen (H₂) therapy — delivered via hydrogen-rich water (HRW), gas inhalation, or H₂-saline infusion — has the strongest clinical evidence for exercise recovery, metabolic syndrome/lipid improvement, oxidative stress reduction, and radiation-induced side effects, with emerging data in rheumatoid arthritis, cancer adjunctive care, and aging. H₂ is notable for its excellent safety profile and unique mechanism as a selective antioxidant that scavenges cytotoxic hydroxyl radicals while preserving physiologically important ROS.
Delivery Methods
H₂ can be administered through several routes: drinking hydrogen-rich water (most common and practical), inhaling H₂ gas (typically 2–4% concentration), intravenous H₂-saline infusion, and topical/bathing applications. Each route has distinct pharmacokinetics — inhalation provides rapid systemic delivery, while oral HRW has been shown to accumulate in hepatic glycogen, potentially explaining why even small amounts produce measurable effects.
Exercise Performance and Muscle Recovery — Most Consistent Human
RCT Data
Multiple double-blind, placebo-controlled crossover trials demonstrate meaningful benefits:
- In resistance-trained men (n = 12), HRW (1,260 mL) reduced blood lactate by 19–23% during exercise (p ≤ 0.008), improved lunge performance speed (p < 0.001), and decreased delayed-onset muscle soreness (DOMS) by 37% at 24 hours (VAS 26 vs. 41 mm, p = 0.002).
- In elite fin swimmers (n = 12), 4 days of HRW supplementation reduced creatine kinase by 18% (156 vs. 190 U/L, p = 0.043), decreased muscle soreness by 19% (p = 0.045), and improved countermovement jump height (p = 0.014) at 12 hours post-exercise.
- In trained men (n = 18), 8 days of HRW intake increased total power output by 9.6% (p = 0.032) and total repetitions by 11.2% (p = 0.019) during half-squat exercise to failure.
Metabolic Syndrome and Lipid/Glucose Metabolism
A meta-analysis of 7 clinical studies found HRW consumption produced significant reductions in total cholesterol (SMD −0.23), LDL-cholesterol (SMD −0.22), and triglycerides (SMD −0.38), all with p = 0.01.
Key individual trials:
- In 20 patients with potential metabolic syndrome, 10 weeks of HRW (0.9–1.0 L/day) significantly decreased serum TC and LDL-C, reduced apoB100 and apoE, and improved HDL functionality across four independent assays (LDL oxidation protection, monocyte adhesion inhibition, cholesterol efflux stimulation, and endothelial cell protection).
- In 36 patients with type 2 diabetes or impaired glucose tolerance, 8 weeks of HRW (900 mL/day) improved electronegative LDL-cholesterol, small dense LDL, and urinary 8-isoprostanes. Notably, 4 of 6 patients with impaired glucose tolerance had normalized oral glucose tolerance tests.
- In 73 patients with impaired fasting glucose, 8 weeks of HRW (1,000 mL/day) produced significantly greater fasting glucose reduction than placebo, with 62.5% achieving fatty liver remission (vs. 31.6% in controls), accompanied by favorable gut microbiota modulation.
- In 181 subjects with metabolic syndrome, 3 months of electrolyzed hydrogen water combined with high physical activity produced a significant reduction in waist circumference compared to controls, with trends toward improved HbA1c, blood glucose, and oxidative stress markers.
Oxidative Stress and Inflammation — Foundational Mechanism
A randomized controlled study (n = 37) demonstrated that a single session of hydrogen inhalation therapy produced a significant reduction in blood reactive oxygen species (d-ROMs) levels in participants with elevated baseline ROS, with effects persisting at 24 hours.
In healthy adults (n = 38), a double-blind RCT showed 4 weeks of HRW (1.5 L/day) significantly reduced PBMC apoptosis, decreased CD14⁺ monocyte frequency, and — via RNA-sequencing — demonstrated clearly distinct transcriptomes with significant downregulation of inflammatory response and NF-κB signaling networks.
The selective antioxidant mechanism is central to H₂'s appeal: unlike conventional antioxidants, H₂ preferentially scavenges the highly cytotoxic hydroxyl radical (•OH) and peroxynitrite (ONOO⁻) while preserving physiologically important ROS (H₂O₂, NO, O₂⁻) needed for normal cell signaling.
Rheumatoid Arthritis
A randomized, double-blind, placebo-controlled pilot study (n = 24) of IV H₂-saline infusion (500 mL daily × 5 days) in RA patients showed the H₂ group's DAS28 decreased from 5.18 to 3.74 at 4 weeks (from high to moderate disease activity), while the placebo group showed no significant change. IL-6 decreased by 37.3%, MMP-3 by 19.2%, and urinary 8-OHdG by 4.7% in the H₂ group. An earlier open-label study found that drinking HRW (530 mL/day × 4 weeks) in 20 early RA patients achieved disease remission (DAS28 < 2.6) in a subset, with the effect most pronounced in early-stage disease.
Cancer — Adjunctive Therapy
Clinical evidence remains early-stage but notable:
- A survey of 82 advanced cancer patients found H₂ inhalation helped control cancer progression and improve quality of life.
- In 55 stage IV colorectal cancer patients, H₂ inhalation enhanced mitochondrial activity via PGC-1α activation and reduced the proportion of terminal PD-1⁺ CD8⁺ T cells — a marker associated with improved cancer prognosis.
- A pilot RCT in head and neck cancer patients undergoing radiotherapy/CCRT found HRW gargling significantly improved oral mucositis at Day 7 (p = 0.04) and Day 14 (p = 0.002), reduced pain at Day 14 (p = 0.02), and improved quality of life (p = 0.03).
- H₂ has been shown to reduce side effects of cisplatin and radiotherapy in preclinical models, with the mechanism attributed to selective scavenging of radiation-generated hydroxyl radicals.
Aging and Neuroprotection
A 6-month RCT in 40 older adults (≥70 years) found HRW (0.5 L/day, 15 ppm) produced a significant increase in telomere length (p = 0.049) — telomeres
lengthened in the HRW group while shortening in controls. HRW also significantly increased TET2 expression (an epigenetic regulator, p = 0.040), improved brain choline and NAA levels on MRS (p < 0.05), and enhanced chair stand performance (p = 0.01).
For neurodegenerative diseases, clinical data remain limited. In patients with mild cognitive impairment, H₂ did not change overall ADAS-cog scores at 1 year, but among APOE4 carriers, 6 of 7 subjects showed improved cognitive scores — suggesting a genotype-specific benefit.
Skin and Wound Healing
A pilot clinical study (n = 15) of topical HRW application for 4 weeks showed significant reduction in pore visibility, with trends toward improved pigmentation, wrinkle severity, and estimated biological skin age. In animal models, HRW dressing significantly accelerated wound closure in both diabetic and non-diabetic rats, with reduced TNF-α and IL-6 levels.
Cardiovascular Protection
Preclinical and mechanistic evidence supports H₂'s cardioprotective effects through anti-inflammatory, antioxidant, and anti-apoptotic pathways, with demonstrated benefits in ischemia-reperfusion injury, atherosclerosis, and radiation-induced cardiac damage models. However, large-scale human cardiovascular outcome trials are lacking.
Safety Profile
H₂ therapy has an exceptionally favorable safety profile. Across all reviewed clinical studies and delivery methods, no serious adverse effects have been reported. H₂ is mild enough to neither disturb metabolic redox reactions nor affect signaling ROS, and it rapidly diffuses through tissues without residue. H₂ gas is non-flammable below 4% concentration in air at room temperature. The primary safety consideration for inhalation is maintaining concentrations below the flammability threshold.